ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Tuesday, November 9, 2021

8:30AM-10:30AM: Abstract Number: 1556

Mortality Rate Related to COVID-19 in Rheumatic and Musculoskeletal Diseases (RMDs)

Infection-related Rheumatic Disease Poster (1530–1564)

8:30AM-10:30AM: Abstract Number: 1495

Multiplexed Profiling of Treatment Naïve Cutaneous Lupus Skin Stratified by Patient Response to Antimalarials

SLE – Etiology & Pathogenesis Poster (1480–1506)

8:30AM-10:30AM: Abstract Number: 1640

Multisystem Inflammatory Syndrome in Children at Two Tertiary Hospitals in Cape Town, South Africa: Clinical Phenotype and Distinguishing Features from Similar Acute Inflammatory Conditions

Pediatric Rheumatology – Clinical Poster III: Miscellaneous Rheumatic Disease (1614–1644)

8:30AM-10:30AM: Abstract Number: 1630

Multisystem Inflammatory Syndrome in Children: Clinical Characteristics and Predictors for Length of Hospitalization

Pediatric Rheumatology – Clinical Poster III: Miscellaneous Rheumatic Disease (1614–1644)

8:30AM-10:30AM: Abstract Number: 1490

Myeloid and B Cell Transcriptional Phenotypes Reveal Race Dependent Differences in Early Autoimmunity

SLE – Etiology & Pathogenesis Poster (1480–1506)

8:30AM-10:30AM: Abstract Number: 1564

Nailfold Capillaroscopy Characterization in COVID-19: A Case Control Study

Infection-related Rheumatic Disease Poster (1530–1564)

8:30AM-10:30AM: Abstract Number: 1635

Nailfold Capillary Microscopy in Children with Raynaud’s Phenomenon. Potential Predictive Value of Capillary Loss for Future Connective Tissue Disease?

Pediatric Rheumatology – Clinical Poster III: Miscellaneous Rheumatic Disease (1614–1644)

8:30AM-10:30AM: Abstract Number: 1783

National Trends in Hospitalizations for Serious Infections in People with Psoriatic Arthritis Using the National Inpatient Sample 2012 – 2017

Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster IV: Clinical Aspects of PsA & Peripheral SpA (1773–1800)

8:30AM-10:30AM: Abstract Number: 1883

Neuro-Behcet’s Disease: 20 Years Single Center Experience of Cyclophosphamide for Induction of Remission

Vasculitis – Non-ANCA-Associated & Related Disorders Poster II (1862–1888)

8:30AM-10:30AM: Abstract Number: 1868

Neutrophil Extracellular Trap Formation in Patients with Vasculitis

Vasculitis – Non-ANCA-Associated & Related Disorders Poster II (1862–1888)

8:30AM-10:30AM: Abstract Number: 1531

New-Onset IgG Autoantibodies in Hospitalized Patients with COVID-19

Infection-related Rheumatic Disease Poster (1530–1564)

8:30AM-10:30AM: Abstract Number: 1578

NLRP3 Inflammasome Pathway Expression at Atheroma Plaques from Peripheral Artery Disease According to the Uricemic Status

Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II (1565–1583)

8:30AM-10:30AM: Abstract Number: 1717

One Year After the Publication of the American College of Rheumatology (ACR) Guidelines for Management of Reproductive Health in Rheumatic Diseases, Has Anything Changed? An Analysis of Rheumatology Practice at a Tertiary Care Medical Center

Reproductive Issues in Rheumatic Disorders Poster (1711–1731)

8:30AM-10:30AM: Abstract Number: 1471

Oral Administration of Berberine Limits Post-traumatic Osteoarthritis Development and Associated Pain via AMP-activated Protein Kinase (AMPK) in Mice

Osteoarthritis & Joint Biology – Basic Science Poster (1468–1479)

8:30AM-10:30AM: Abstract Number: 1523

Outcomes and Disease Characteristics in Patients with Rheumatoid Arthritis Treated with Immune Checkpoint Inhibitors for Malignancy at a Single Academic Institution

Immunological Complications of Therapy Poster (1516–1529)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].